LY6L

Across TCGA pan-cancer cohorts, LY6L RNA differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of LY6L’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where LY6L RNA is repressed in tumor relative to normal tissue. In most cancer types LY6L is over-expressed in tumor, although a few such as KIRC and KIRP show the opposite, repressed pattern.

KIRC, KIRP, and THCA are the cancer types where LY6L tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LY6L RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	All	−0.799	<.001	11	view →
KIRP	Male	II,III,IV	−0.989	<.001	8	view →
THCA	All	All	−0.026	.002	4	view →
KICH	Male	IV	−1.053	.001	3	view →
PRAD	All	All	−0.362	.010	2	view →
UCEC	All	IV	+0.150	.037	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

LY6L–KIRC

Open the KIRC breakdown →